Jun-Xiong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun-Xiong Li has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jing Li
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
2 shared publications - Wenjia Wang
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China
2 shared publications - Huangan Wu
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication Jing Xie
Yueyang Hospital of Integrated Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China
1 shared publicationLu Zhu
Department of Acupuncture, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China
1 shared publicationMeng-Die Wu
Department of Acupuncture, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-18
Acupuncture for Postherpetic Neuralgia: An Evidence Mapping
Objective: This study is to systematically evaluate the efficacy of acupuncture for PHN and provide a visual overview of treatment landscape. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang Database for systematic reviews (SRs) on acupuncture for PHN up to Apr 18, 2025. Studies were included if they were SRs of randomized controlled trials (RCTs) assessing traditional Chinese acupuncture interventions for PHN, and excluded if they involved non-traditional acupuncture, herpes zoster, or PHN prevention research. Two independent reviewers utilized Excel, EndNote 20, and R software for data analysis and assessed the quality of included studies using the AMSTAR2 tool. Results: Of 351 identified records, 40 SRs met inclusion criteria, encompassing 926 RCTs, 63,493 patients, 13 types of acupuncture interventions and 29 outcomes. Acupuncture interventions, particularly fire needling, CPBLC, Fu’s subcutaneous needling, plum-blossom needle, multi-acupuncture and multi-acupuncture + pharmacotherapy, showed the most robust benefits in improving effective rate, reducing visual analog scale (VAS) scores, and decreasing adverse reactions in PHN treatment. Despite most SRs reporting positive outcomes, the quality was generally low by AMSTAR2. Conclusion: Acupuncture could be a valuable adjunct to standard PHN treatment, offering benefits in overall efficacy, pain management and treatment safety. However, high-quality clinical trials and systematic reviews are needed to confirm these preliminary results and guide clinical practice.
- 1 June 2026
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 19, 1-18
Open AccessAcupuncture for Postherpetic Neuralgia: An Evidence Mapping
Objective: This study is to systematically evaluate the efficacy of acupuncture for PHN and provide a visual overview of treatment landscape. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang Database for systematic reviews (SRs) on acupuncture for PHN up to Apr 18, 2025. Studies were included if they were SRs of randomized controlled trials (RCTs) assessing traditional Chinese acupuncture interventions for PHN, and excluded if they involved non-traditional acupuncture, herpes zoster, or PHN prevention research. Two independent reviewers utilized Excel, EndNote 20, and R software for data analysis and assessed the quality of included studies using the AMSTAR2 tool. Results: Of 351 identified records, 40 SRs met inclusion criteria, encompassing 926 RCTs, 63,493 patients, 13 types of acupuncture interventions and 29 outcomes. Acupuncture interventions, particularly fire needling, CPBLC, Fu’s subcutaneous needling, plum-blossom needle, multi-acupuncture and multi-acupuncture + pharmacotherapy, showed the most robust benefits in improving effective rate, reducing visual analog scale (VAS) scores, and decreasing adverse reactions in PHN treatment. Despite most SRs reporting positive outcomes, the quality was generally low by AMSTAR2. Conclusion: Acupuncture could be a valuable adjunct to standard PHN treatment, offering benefits in overall efficacy, pain management and treatment safety. However, high-quality clinical trials and systematic reviews are needed to confirm these preliminary results and guide clinical practice.
- Open Access
- 1 July 2022
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 15, 1889-1896
Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial
Background: Cancer-related pain is one of the primary symptoms of patients with hepatocellular carcinoma (HCC). Previous studies have shown that transcutaneous electrical acupoint stimulation (TEAS) is effective in treating patients with acute or chronic pain. In China, it is indispensable to evaluate the efficacy of TEAS in combination with opioids for the treatment of moderate to severe HCC-related pain. Methods/Design: This is a single-center clinical, prospective randomized controlled clinical trial protocol. 104 patients will be randomly divided into the observation group and the control group in a ratio of 1:1.In addition to routine cancer pain medication, the two groups of patients will receive TEAS treatment twice a day for one week. Acupoints will include bilateral Hegu(LI4), Neiguan(PC6), Zusanli(ST36), Taichong(LR3), Ganshu(BL18), Geshu(BL17), Qimen(LR14), and Zhangmen(LR13). The treatment time is from 9:00 a.m. to 11:00 p.m. and from 4:00 p.m. to 6:00 p.m. The primary outcome measures are the Numerical Rating Scale (NRS) and the secondary outcome measures include the Brief Pain Inventory(BPI), dosage and administration duration of opioid drugs, frequency of nausea, vomiting and defecation, Karnofsky Performance Status Scale (KPS), Quality of life scale (QOL), Brief Fatigue Inventory (BFI). The outcome measures will be evaluated at baseline, during treatment and 1 week after treatment. Discussion: Results of this trial are expected to clarify the value of TEAS stimulation performed on specific points in the management of moderate to severe pain in HCC. Trial registration: Chinese clinical trial registry, ChiCTR2100044615 (http://www.chictr.org.cn), Registered on 24 March 2021.
- 1 July 2022
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 15, 1889-1896
Open AccessTranscutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial
Background: Cancer-related pain is one of the primary symptoms of patients with hepatocellular carcinoma (HCC). Previous studies have shown that transcutaneous electrical acupoint stimulation (TEAS) is effective in treating patients with acute or chronic pain. In China, it is indispensable to evaluate the efficacy of TEAS in combination with opioids for the treatment of moderate to severe HCC-related pain. Methods/Design: This is a single-center clinical, prospective randomized controlled clinical trial protocol. 104 patients will be randomly divided into the observation group and the control group in a ratio of 1:1.In addition to routine cancer pain medication, the two groups of patients will receive TEAS treatment twice a day for one week. Acupoints will include bilateral Hegu(LI4), Neiguan(PC6), Zusanli(ST36), Taichong(LR3), Ganshu(BL18), Geshu(BL17), Qimen(LR14), and Zhangmen(LR13). The treatment time is from 9:00 a.m. to 11:00 p.m. and from 4:00 p.m. to 6:00 p.m. The primary outcome measures are the Numerical Rating Scale (NRS) and the secondary outcome measures include the Brief Pain Inventory(BPI), dosage and administration duration of opioid drugs, frequency of nausea, vomiting and defecation, Karnofsky Performance Status Scale (KPS), Quality of life scale (QOL), Brief Fatigue Inventory (BFI). The outcome measures will be evaluated at baseline, during treatment and 1 week after treatment. Discussion: Results of this trial are expected to clarify the value of TEAS stimulation performed on specific points in the management of moderate to severe pain in HCC. Trial registration: Chinese clinical trial registry, ChiCTR2100044615 (http://www.chictr.org.cn), Registered on 24 March 2021.